Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 4/20 | 0.57 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.57 |
| ▸ | STAT3 | P40763 | 4/20 | 0.57 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.57 |
| ▸ | RELA | Q04206 | 3/20 | 0.57 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.57 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.57 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.57 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.57 |
| ▸ | TNFRSF1A | P19438 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2743834 | 1.00 | CYP1A2 (0.61) | CYP1A2CYP2D6CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL2743682 | 0.89 | CYP1A2 (0.50) | CYP1A2CYP2D6CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL2743681 | 0.89 | CYP1A2 (0.50) | CYP1A2CYP2D6CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL2744009 | 0.87 | TNFRSF1A (0.60) | CYP1A2CYP2D6CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL2743909 | 0.83 | ALDH1A1 (0.77) | CYP1A2CYP2D6CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL2743907 | 0.83 | ALDH1A1 (0.77) | CYP1A2CYP2D6CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL2744007 | 0.83 | CYP1A2 (0.52) | CYP1A2CYP2D6CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL2744012 | 0.83 | CYP1A2 (0.52) | CYP1A2CYP2D6CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL2743979 | 0.83 | CYP1A2 (0.59) | CYP1A2CYP2D6CYP3A4CYP2C9CYP2B6 | |
| SCHEMBL2743978 | 0.83 | CYP1A2 (0.59) | CYP1A2CYP2D6CYP3A4CYP2C9CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178727-B2 | Bis(arylmethylidene)acetone compound, anti-cancer agent, carcinogenesis-preventive agent, inhibitor of expression of Ki-Ras, ErbB2, c-Myc and Cycline D1, β-catenin-degrading agent, and p53 expression enhancer | NATIONAL UNIVERSITY CORPORATION TOHOKU UNIVERSITY (JP) | 2012-05-15 | — | — | US | claimed |
| US-20100152493-A1 | BIS(ARYLMETHYLIDENE)ACETONE COMPOUND, ANTI-CANCER AGENT, CARCINOGENESIS-PREVENTIVE AGENT, INHIBITOR OF EXPRESSION OF Ki-Ras, ErbB2, c-Myc AND CYCLINE D1, BETA-CATENIN-DEGRADING AGENT, AND p53 EXPRESSION ENHANCER | SHIBATA, HIROYUKI (JP) | 2010-06-17 | — | — | US | claimed |
| US-20250093345-A1 | Optical biomodule for detection of diseases at an early onset | MAZED MOHAMMAD A (US) | 2025-03-20 | — | — | US | disclosed |
| US-12135286-B1 | Optical biomodule for detection of diseases at an early onset | MAZED MOHAMMAD A (US) | 2024-11-05 | — | — | US | disclosed |
| US-11747279-B2 | Optical biomodule for detection of diseases at an early onset | MAZED MOHAMMAD A (US) | 2023-09-05 | — | — | US | disclosed |
| US-8178727-B2 | Bis(arylmethylidene)acetone compound, anti-cancer agent, carcinogenesis-preventive agent, inhibitor of expression of Ki-Ras, ErbB2, c-Myc and Cycline D1, β-catenin-degrading agent, and p53 expression enhancer | NATIONAL UNIVERSITY CORPORATION TOHOKU UNIVERSITY (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20100152493-A1 | BIS(ARYLMETHYLIDENE)ACETONE COMPOUND, ANTI-CANCER AGENT, CARCINOGENESIS-PREVENTIVE AGENT, INHIBITOR OF EXPRESSION OF Ki-Ras, ErbB2, c-Myc AND CYCLINE D1, BETA-CATENIN-DEGRADING AGENT, AND p53 EXPRESSION ENHANCER | SHIBATA, HIROYUKI (JP) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152493-A1 | BIS(ARYLMETHYLIDENE)ACETONE COMPOUND, ANTI-CANCER AGENT, CARCINOGENESIS-PREVENTIVE AGENT, INHIBITOR OF EXPRESSION OF Ki-Ras, ErbB2, c-Myc AND CYCLINE D1, BETA-CATENIN-DEGRADING AGENT, AND p53 EXPRESSION ENHANCER | MYC, CCNE2, CCNE1 | CYP1A2 1717/4885CYP2D6 1871/4885CYP3A4 2309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.